Mena-Vázquez, NataliaManrique Arija, SaraRojas-Giménez, MartaRaya-Álvarez, EnriqueVelloso-Feijoó, María LuisaLópez-Medina, CRamos-Giraldez, ConsueloGodoy-Navarrete, Francisco JavierRedondo-Rodríguez, RocíoCabezas-Lucena, Alba MaríaMorales-Águila, MRomero-Barco, C MFernández-Nebro, Antonio2025-01-072025-01-072021-03-20https://hdl.handle.net/10668/26144To describe whether rheumatic inflammatory diseases (RID) are associated with a higher risk of hospitalization and/or mortality from COVID-19 and identify the factors associated with hospitalization and mortality in RID and COVID-19 in different Hospitals in Andalusia. Design: Multicentre observational case-control study. RID and COVID-19 from different centres in Andalusia. patients without RIS matched by sex, age and CRP-COVID. Protocol A list of patients with PCR for COVID-19 was requested from the microbiology service from March 14 to April 14, 2020. The patients who had RID were identified and then consecutively a paired control for each case. Variables The main outcome variable was hospital admission and mortality from COVID-19. Statistical analysis Bivariate followed by binary logistic regression models (DV: mortality/hospital admission). One hundred and fifty-six patients were included, 78 with RID and COVID-19 and 78 without RID with COVID-19. The patients did not present characteristics of COVID-19 disease different from the general population, nor did they present higher hospital admission or mortality. The factor associated with mortality in patients with RID was advanced age (OR [95% CI], 1.1 [1.0-1.2]; p = 0.025), while the factors associated with hospitalization were advanced age (OR [95% CI], 1.1 [1.0-1.1]; p = 0.007) and hypertension (OR [95% CI], 3.9 [1.5-6.7]; p = 0.003). Mortality and hospital admission due to COVID-19 do not seem to increase in RID. Advanced age was associated with mortality in RID and, in addition, HTN was associated with hospital admission.enCOVID-19Enfermedad inflamatoria reumáticaHospitalizaciónHospitalizationMortalidadMortalityRheumatic inflammatory diseaseresearch article33895100open access10.1016/j.reuma.2021.02.0092173-5743PMC7980141https://doi.org/10.1016/j.reuma.2021.02.009https://pmc.ncbi.nlm.nih.gov/articles/PMC7980141/pdf